How C-Peptide Guides Treatment

C-peptide is released alongside insulin in equal amounts, so measuring it tells your doctor how much insulin your pancreas is still producing. In LADA that number does most of the work in deciding treatment.

The logic is straightforward. If you are still producing a reasonable amount, tablets can do something useful and there is beta-cell function worth protecting. If production has already fallen low, no tablet can create insulin that is not being made, and injections are needed.

This is why C-peptide is repeated rather than measured once. A single value is a snapshot; the trend across two or three years shows how quickly you are moving, and that is what predicts when your regimen will need to change.

Two ways of measuring exist. A fasting sample is easier and cheaper. A stimulated sample, taken after a measured meal or drink, shows what your pancreas can produce under demand and predicts the timing of insulin more reliably.

C-peptide also does something useful for confidence. When treatment intensifies, it is natural to wonder whether the change was really necessary. A falling C-peptide answers that with a measurement rather than an opinion.

It cannot, on its own, diagnose LADA — a low result occurs in long-standing Type 2 diabetes too. It is the antibody test that establishes the cause, and C-peptide that tracks the consequence.